Yahoo
    NasdaqGS - Nasdaq Real Time Price USD

    Nanobiotix S.A. (NBTX)

    28.11 -3.26 (-10.39%)
    At close: November 2 at 4:00:01 PM EST
    Trade NBTX on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for NBTX
    Chart does not reflect overnight price.
    • Previous Close 31.37
    • Open 30.39
    • Bid 26.50 x 100
    • Ask 21.51 x 100
    • Day's Range 27.49 - 30.46
    • 52 Week Range 17.42 - 57.14
    • Volume 119,201
    • Avg. Volume 149,325
    • Market Cap (intraday) 1.432B
    • Beta (5Y Monthly) 0.53
    • PE Ratio (TTM) --
    • EPS (TTM) -1.27
    • Earnings Date (est.) Sep 29, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 54.38
    • Zacks Rating Neutral

    Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

    www.nanobiotix.com

    98

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Nanobiotix S.A.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

    YTD Return

    NBTX
    29.72%
    CAC 40 (^FCHI)
    1.25%

    1-Year Return

    NBTX
    34.69%
    CAC 40 (^FCHI)
    0.90%

    3-Year Return

    NBTX
    352.66%
    CAC 40 (^FCHI)
    13.98%

    5-Year Return

    NBTX
    158.72%
    CAC 40 (^FCHI)
    16.18%

    Earnings Trends

    View More

    Earnings Per Share

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q4 FY21
    Revenue --
    Earnings -8.29M
    Profit Margin 0.00%

    Q1

    FY21

    Q2

    FY21

    Q3

    FY21

    Q4

    FY21

    -15M
    -10M
    -5M
    0
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    30.14
    54.38 Average
    28.11 Current
    69.98 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 6/4/2026
    Analyst Leerink Partners
    Rating Action Maintains
    Rating Outperform
    Price Action Raises
    Price Target 37 -> 46
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -21.34%

    • Return on Equity (ttm)

      --

    • Revenue (ttm)

      11.51M

    • Net Income Avi to Common (ttm)

      -52.87M

    • Diluted EPS (ttm)

      -1.27

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      110.89M

    • Total Debt/Equity (mrq)

      --

    • Levered Free Cash Flow (ttm)

      -32.78M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    PHVS Pharvaris N.V.
    32.95 -1.73%
    FDMT 4D Molecular Therapeutics, Inc.
    11.37 -4.45%
    IVA Inventiva S.A.
    3.8300 +4.93%
    INBX Inhibrx Biosciences, Inc.
    72.16 +0.53%
    OLMA Olema Pharmaceuticals, Inc.
    7.07 +1.00%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: